Cravens & Co Advisors LLC Raises Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Cravens & Co Advisors LLC boosted its position in Novo Nordisk A/S (NYSE:NVO) by 1.6% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 8,097 shares of the company’s stock after purchasing an additional 128 shares during the period. Cravens & Co Advisors LLC’s holdings in Novo Nordisk A/S were worth $964,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. 1620 Investment Advisors Inc. bought a new position in shares of Novo Nordisk A/S during the second quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S in the second quarter worth $25,000. Gilliland Jeter Wealth Management LLC raised its holdings in Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after purchasing an additional 120 shares in the last quarter. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S in the third quarter worth $28,000. Finally, Halpern Financial Inc. raised its holdings in Novo Nordisk A/S by 113.0% in the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on NVO. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Finally, BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Trading Up 1.5 %

Novo Nordisk A/S stock opened at $106.15 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The stock has a market capitalization of $476.35 billion, a PE ratio of 34.35, a price-to-earnings-growth ratio of 1.35 and a beta of 0.42. The business’s fifty day moving average is $114.32 and its 200 day moving average is $128.49.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.